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Abstract 
Background and aim:  Low density lipoprotein cholesterol (LDL-C) is a primary risk factor for 
atherosclerosis, but it is also associated with elevated blood pressure (BP) and future development of 
hypertension. We examined the relationship between LDL-C and haemodynamic variables in 
normotensive and never-treated hypertensive subjects. 
Methods: We recruited 615 volunteers (19-72 years) without lipid-lowering and BP-lowering 
medication. Supine haemodynamics were recorded using continuous radial pulse wave analysis, whole-
body impedance cardiography, and single channel electrocardiogram. The haemodynamic relations of 
LDL-C were examined using linear regression analyses with age, sex, body mass index (BMI) (or 
height and weight as appropriate), smoking status, alcohol use, and plasma C-reactive protein, sodium, 
uric acid, high density lipoprotein cholesterol (HDL-C), triglycerides, estimated glomerular filtration 
rate, and quantitative insulin sensitivity check index as the other included variables. 
Results: The mean (SD) characteristics of the subjects were: age 45 (12) years, BMI 27 (4) kg/m2, 
office BP 141/89 (21/13) mmHg, creatinine 74 (14) µmol/l, total cholesterol 5.2 (1.0), LDL-C 3.1 (0.6), 
triglycerides 1.2 (0.8), and HDL-C 1.6 (0.4) mmol/l. LDL-C was an independent explanatory factor for 
aortic systolic and diastolic BP, augmentation index, pulse wave velocity (PWV), and systemic 
vascular resistance index  (p<0.05 for all). When central BP was included in the model for PWV, LDL-
C was no longer an explanatory factor for PWV. 
Conclusions: LDL-C is independently associated with BP via systemic vascular resistance and wave 
reflection. These results suggest that LDL-C may play a role in the pathogenesis of primary 
hypertension. 
Keywords: augmentation index, haemodynamics, hypertension, impedance cardiography, LDL 
cholesterol, pulse wave analysis, systemic vascular resistance 
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Introduction 
Cardiovascular diseases are the leading cause of mortality worldwide representing 31% of all global 
deaths [1]. One fourth of all deaths in the Western countries are related to coronary heart disease [2]. 
Subjects with familial hypercholesterolemia are characterized by premature atherosclerosis, and the 
pathogenic role of low density lipoprotein cholesterol (LDL-C) in this process is well recognized [3]. 
LDL-C has also vasoconstrictor, pro-inflammatory and thrombogenic properties, and it functions as a 
mitogenic factor that can stimulate vascular hypertrophy via several growth factors [4].  
Previous studies have reported that LDL-C is associated with arterial stiffness, shown as increased 
pulse wave velocity (PWV) [5], or reduced aortic compliance using ultrasound measurements [6,7]. A 
positive correlation between LDL-C and PWV was also observed in a group of 315 children aged 8–9 
years [8]. However, according to a systematic review, less than 10% of studies demonstrated a positive 
correlation between serum lipids and arterial stiffness, and therefore the influence of risk factors other 
than age and blood pressure (BP) on PWV appears to be small [9]. 
Dyslipidaemias are not only a risk factor for cardiovascular disease, but can also predict the future 
development of hypertension [10–13] and impairment of endothelial function [14]. LDL-C can reduce 
nitric oxide bioavailability and blunt the vasodilator response to acetylcholine [4,14–17], and the 
resulting endothelial dysfunction could be manifested as increased BP. Following treatment with 
statins, several trials have shown moderate but statistically significant lowering effect on BP [18–23], 
reduction of arterial stiffness [19,20,24], and improved endothelial function [25,26]. 
Some previous studies that addressed the association of LDL-C with haemodynamic variables included 
subjects taking antihypertensive medications and even diabetic patients [5–7]. The objective of this 
cross-sectional study was to investigate the association of LDL-C with haemodynamic variables that 
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could potentially explain differences in BP between normotensive subjects and never-treated patients 
with primary hypertension. 
 
Methods 
Participants 
All subjects participated in an ongoing study with the aim to examine haemodynamics in primary and 
secondary hypertension versus normotension (DYNAMIC study; ClinicalTrails.gov identifier 
NCT01742702). The participant recruitment has been described before [27,28], and the study flow-
chart is presented in Supplementary Figure 1. Subjects taking lipid-lowering or BP-lowering 
medication or with a history of coronary artery disease, stroke, heart failure, valvular heart disease, 
diabetes, chronic kidney disease, secondary hypertension, alcohol or substance abuse, psychiatric 
illnesses, or heart rhythm other than sinus were excluded (total number of enrolled subjects 1349). All 
subjects underwent physical examination by a medical doctor, measurement of office BP, and routine 
laboratory analyses for elevated BP according to the guidelines of the European Society of 
Hypertension [29]. The medical history, lifestyle habits and use of medicines, dietary supplements, and 
other substances not registered as drugs were documented along with information about smoking and 
alcohol consumption as standard drinks (~12 grams of absolute alcohol) per week.  
A total of 615 normotensive and never-treated subjects with primary hypertension, aged 19-72 years, 
were included in the study. Based on the office BP measurements on a single occasion, 249 (40.5%) of 
the participants were normotensive and 366 (59.5%) were hypertensive. For the graphical illustrations, 
they were divided into age- and sex-adjusted LDL-C quartiles (Q1, n=153; Q2, n=158; Q3, n=148; Q4, 
n=156). Signed informed consent was obtained from all participants. The study complies with the 
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declaration of Helsinki, and was approved by the ethics committee of the Tampere University Hospital 
(study code R06086M) and the Finnish Medicines Agency (Eudra-CT registration number 2006-
002065-39). 
Altogether 230 (37.4%) of the 615 persons used some medications. Seventy-six females were treated 
with systemic oestrogen, progestin, or their combination (contraception, hormone replacement 
therapy), and 1 subject with tibolone. Forty-one subjects were treated with antidepressants, 18 with 
antihistamines, 17 with inhaled corticosteroids, 13 with proton pump inhibitors, while 22 euthyroid 
subjects were on a stable dose of thyroid hormone. Other medications in use were hypnotics or 
sedatives (8), low dose acetylsalicylic acid (6), non-steroidal anti-inflammatory drugs (4), 
antirheumatic agents (4), antiepileptics (3), allopurinol (3), coxibs (3), antipsychotics (2), muscle 
relaxants (2), varenicline (2), antiviral agents (2), paracetamol (1), carbimazole (1), isotretinoin (1), and 
alendronate (1). One subject was treated with warfarin because of an anti-phospholipid syndrome, and 
she was physically well and symptomless during the recordings. 
 
Laboratory analyses 
Blood and urine sampling was preceded by about 12 hours of fasting. Plasma total, high density 
lipoprotein cholesterol (HDL-C), LDL-C, triglyceride, C-reactive protein (CRP), sodium, potassium, 
glucose, cystatin-C, and creatinine concentrations were determined using Cobas Integra 700/800 (F. 
Hoffmann-Laroche Ltd, Basel; Switzerland) or Cobas6000, module c501 (Roche Diagnostics, Basel, 
Switzerland), insulin using electrochemiluminescence immunoassay (Cobas e411, Roche Diagnostics), 
and blood cell count by ADVIA 120 or 2120 (Bayer Health Care, Tarrytown, NY, USA). Urine 
dipstick analysis was made by an automated refractometer test (Siemens Clinitec Atlas or Advantus, 
  
6 
 
Siemens Healthcare GmbH, Erlangen, Germany). For evaluation of insulin sensitivity the quantitative 
insulin sensitivity check index (QUICKI) [30] was calculated, and glomerular filtration rate (eGFR) 
was estimated using the CKD-EPI cystatin C formula [31]. 
 
Pulse wave analysis 
Radial BP and pulse wave were continuously recorded from radial pulsation using a tonometric sensor 
(Colin BP-508T, Colin Medical Instruments Corp., USA), secured on the radial pulse with a wrist 
band. The radial BP signal was calibrated twice during each 5 minute-period by contralateral brachial 
BP measurements. Aortic BP was derived with the SphygmoCor system (SpygmoCor PWMx®, AtCor 
medical, Australia) by means of the validated generalized transfer function [32]. Left ventricular 
ejection duration, aortic pulse pressure and reflection time, augmentation index (AIx, augmented 
pressure/pulse pressure*100), AIx adjusted to heart rate 75/min (AIx@75), and amplification of pulse 
pressure and systolic pressure (radial pressure/aortic pressure) were determined [27,28]. 
 
Whole-body impedance cardiography 
Beat-to-beat heart rate, stroke volume, cardiac output, and PWV were recorded using whole-body 
impedance cardiography (CircMon®, JR Medical Ltd., Tallinn, Estonia) that detects changes in body 
electrical impedance during cardiac cycles. The method and electrode configuration have been 
previously reported [33]. Systemic vascular resistance (SVR) was calculated from the tonometric BP 
signal and cardiac index measured by CircMon®. SVR was calculated by subtracting normal central 
venous pressure (4 mmHg) from mean arterial pressure and dividing it by cardiac output. SVR and 
cardiac output were presented as indexes related to body surface area – cardiac index, and systemic 
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vascular resistance index (SVRI), respectively. The stroke volume values measured using CircMon® 
correlate well with 3 dimensional ultrasound [34]. The supine cardiac output values measured with 
CircMon® correlate well with the values measured using thermodilution [33]. The whole-body 
impedance cardiography tends to overestimate PWV, and a validated equation was utilized to calculate 
values correspond to the ultrasound method (PWV = PWVimpedance * 0.696 + 0.864) [35]. By the use 
of this equation, the PWV values recorded using CircMon® show very good correlations with values 
measured using either ultrasound (r=0.91) [35] or the tonometric SphygmoCor® method (r=0.82, bias 
0.02 m/s, 95% confidence interval  -0.21 to 0.25) [28]. 
 
Experimental protocol 
Haemodynamics were recorded in a quiet, temperature-controlled laboratory by research nurses [36]. 
Caffeine containing products, smoking or heavy meals were to be avoided for ≥4 hours, and alcohol 
consumption for >24 hours prior to the studies. The subjects rested supine, the left arm with the 
tonometric sensor abducted to 90 degrees in an arm support. After getting accustomed to the laboratory 
for about 10 minutes, supine haemodynamics were recorded for five minutes. For the statistical 
analyses the mean values of each 1-minute period of recording were calculated. The good repeatability 
and reproducibility of the measurement protocol has been demonstrated [37]. 
 
Statistics 
Continuous variables were expressed as the mean and standard deviation (SD) or standard error of the 
mean (SEM). Baseline characteristics were depicted as age- and sex-adjusted quartiles of LDL-C 
(Table 1). The demographic and laboratory data was analysed using analysis of variance (ANOVA), 
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and the Bonferroni correction was applied in the post-hoc analyses. The homogeneity of variances was 
tested with the Levene’s test. For the illustrations, the haemodynamic differences between the quartiles 
were examined using ANOVA for repeated measures adjusted for age and sex. Spearman’s correlations 
(rS) were calculated, as appropriate.  
A multiple regression analysis with stepwise elimination was applied to evaluate the associations 
between age, sex, body mass index (BMI) (for systemic vascular resistance index BMI was replaced by 
height and weight), smoking status, alcohol consumption, QUICKI, plasma CRP, sodium, uric acid, 
HDL-C, LDL-C, triglycerides, and eGFR (independent variables), and aortic systolic and diastolic BP, 
aortic pulse pressure, AIx, PWV and SVRI (dependent variables) in model 1. The variables in model 2 
were model 1 + PWV (independent variables) for aortic systolic and diastolic BP, aortic pulse pressure 
(dependent variables); for AIx (dependent variable): model 1 + heart rate, SVRI, and PWV 
(independent variables); for PWV (dependent variable): model 1 + aortic systolic BP (independent 
variables). For these analyses the skewed distribution of PWV was corrected by lg10-transformation. 
P<0.05 was considered statistically significant. SPSS version 22.0 (IBM SPSS Statistics, Armonk, NY, 
USA) was used for the statistics. 
 
 
Results 
Study population and laboratory values 
In total, 615 subjects were included in the analyses, consisting of 314 male (51%) and 301 female 
(49%) subjects (Table 1). The age range was 19–72 years, mean (SD) age was 44.9 (11.9) years, BMI 
26.8 (4.4) kg/m2, office systolic/diastolic BP 140.5 (21.1) / 89.3 (12.5) mmHg, creatinine 73.7 (13.5) 
μmol/l, total cholesterol 5.2 (1.0), LDL-C 3.1 (0.6), triglycerides 1.2 (0.8) and HDL-C 1.6 (0.4) mmol/l 
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(Table 1).  Altogether 80 (13%) of the subjects had impaired fasting plasma glucose (6.1-7.0 mmol/l), 
while in 6 subjects (1%) the fasting plasma glucose was in the range of 7.1-10.3 mmol/l. However, 
none of the study participants had glucosuria or proteinuria in the morning urine sample. 
For the graphical illustrations the participants were divided into age- and sex-adjusted LDL-C quartiles. 
The average LDL-C in the quartiles ranged from 2.05 (0.51) (Q1) to 4.15 (0.75) (Q4) mmol/l (Table 1). 
After adjustments for age and sex, the quartiles presented with differences in BMI, office systolic and 
diastolic BP, eGFR, QUICKI, and plasma cystatin C, total cholesterol, triglycerides, HDL-C, and 
glucose concentrations (Table 1). Alcohol intake, smoking status, and plasma creatinine, sodium, 
potassium, uric acid, CRP, and insulin concentrations were not significantly different between the 
quartiles. 
 
Haemodynamic variables in the quartiles of LDL-C adjusted for age and sex 
Aortic and radial systolic and diastolic BP were not significantly different in adjacent quartiles, but 
were different in all other comparisons between the quartiles, so that the highest LDL-C quartile (Q4) 
presented with the highest BP (Figures 1A-1B, Supplementary Figures 2A-2B). Aortic pulse pressure 
differed between the highest (Q4) and lowest LDL-C quartile (Q1) (Figure 1C), while AIx (Figure 1D) 
and AIx@75 (Supplementary Figure 2C), and heart rate and cardiac index (Figures 2A-2B) were not 
significantly different between the quartiles. SVRI differed between Q4 and Q1 (Figure 2C), while 
PWV was higher in Q4 than in Q1 and Q2 (Figure 2D). 
 
LDL-C and haemodynamic variables in stepwise linear regression analyses 
We performed linear regression analyses to examine the relationships between the haemodynamic 
variables and age, sex, BMI (for systemic vascular resistance index replaced by height and weight), 
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smoking status, weekly alcohol consumption, insulin sensitivity (QUICKI) [30], cystatin C based 
eGFR [31], and plasma CRP, sodium, uric acid, HDL-C, LDL-C, and triglyceride concentrations 
(model 1, Table 2).  These analyses showed that LDL-C was a significant independent explanatory 
factor for aortic systolic and diastolic BP, aortic pulse pressure, AIx, PWV, and SVRI (p<0.05 for all) 
(model 1, Table 2).   
The model 2 for aortic systolic and diastolic BP, and aortic pulse pressure included PWV in addition to 
the above variables of model 1 (model 2, Table 2). These results showed that LDL-C was a significant 
independent explanatory factor for aortic systolic and diastolic BP (p<0.05 for all), while in this model 
LDL-C was no more an explanatory factor for aortic pulse pressure. 
The model 2 for AIx contained the variables heart rate, SVRI and PWV in addition to the above 
variables of model 1. The outcome was that LDL-C, smoking status, sex, age, BMI, heart rate, and 
SVRI were independent significant explanatory factors for AIx (model 2, Table 2).  
The model 2 for PWV contained aortic systolic BP in addition to the variables of model 1. In this 
model LDL-C was no more an explanatory factor for PWV. The significant explanatory factors for 
PWV were age, aortic systolic BP, uric acid, triglycerides, HDL-C, smoking status and sodium (model 
2, Table 2). If aortic mean BP or aortic diastolic BP was used in the model 2 instead of aortic systolic 
BP, LDL-C was not an independent explanatory factor for PWV, either (not shown). 
 
Discussion 
LDL-C is an established risk factor for atherosclerosis and endothelial dysfunction, but it has also been 
linked with elevated BP [10,11,18,20]. We examined the relations of LDL-C with several 
cardiovascular variables using non-invasive recordings of haemodynamics. The present results 
indicated that LDL-C was independently associated with BP, AIx, and SVRI. LDL-C was also 
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associated with increased PWV, but the relation between PWV and LDL-C was no longer significant 
when central BP was included in the model.  
Increased large artery stiffness, manifested as accelerated PWV and elevated pulse pressure, increases 
with aging and is an independent cardiovascular risk factor [38]. As atherosclerosis and plaque 
formation alter the properties of the arterial wall, the measures of arterial stiffness have been 
considered as surrogate markers of atherosclerosis [9,39]. Due to the central role of LDL-C in 
atherosclerosis, its relation with arterial stiffness would seem evident, and a positive correlation 
between LDL-C and PWV has been reported [5–8]. However, the relationship between LDL-C and 
arterial stiffness, a process characterized by increased fibrosis and collagen deposition in the arterial 
wall, remains controversial: according to a comprehensive review, the majority of studies did not find a 
positive correlation between serum lipids and arterial stiffness, as measured using determinations of 
PWV [9]. 
In addition to age, PWV is strongly dependent on the prevailing level of BP [9,39]. In our study LDL-C 
was associated with PWV, but when central BP was included in the regression model, LDL-C was no 
more an explanatory factor for arterial stiffness. Our results indicated that triglyceride concentration 
was directly, and HDL-C was inversely, associated with PWV in the linear regression model 2. 
Previously, higher triglyceride and lower HDL-C levels have been associated with increased PWV 
[40,41]. Of note, the characteristic components of the metabolic syndrome, i.e. lower HDL-C, higher 
triglycerides, and higher uric acid were all associated with higher PWV in the present statistical model 
2, corresponding to previous findings [27,40]. The influence of glucose metabolism on haemodynamics 
was taken into consideration in the regression analyses by the inclusion of the QUICKI index in the 
variables. Many reports support the view that statins can improve arterial stiffness [19,20,24]. The 
present results raise the possibility that the lowering effect of statins on PWV could partially be 
mediated via the beneficial effect on central BP. 
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LDL-C may be a significant risk factor for the development of hypertension. Laaksonen et al. found 
that abnormal LDL-C and triglyceride metabolism predicted future development of hypertension in 
middle-aged men [11]. In a study comprising 20,074 subjects, the incidence of new onset of 
hypertension was lower in subjects with lower LDL-C [13]. Several studies have revealed small but 
significant reductions in BP after treatment with statins [18,19,22,23]. A meta-analysis comprising 828 
subjects reported a decrease of BP by 1.9/0.9 mmHg following statin therapy that was unrelated to age, 
changes in serum cholesterol, or length of the trial [21].  Another meta-analysis including 22,602 statin-
treated patients and 22,511 controls found that statins decreased BP by 2.62/0.94 mmHg, an effect that 
was not related to patient age, follow-up duration, or the evaluated quality of the study [22]. In the 
Anglo-Scandinavian Cardiac Outcomes Trial, 10,305 hypertensive patients were randomly assigned to 
receive atorvastatin 10 mg daily or placebo for a median follow-up of 3.3 years [42]. Office BP 
throughout the trial was similar in the atorvastatin and placebo groups. However, no conclusions could 
be drawn about the lack of BP-lowering effect of atorvastatin in this study, as antihypertensive 
medication was titrated upwards based on achieved BP, and this potentially masked any impact of 
atorvastatin on BP [42]. 
Endothelial dysfunction can be manifested as elevated BP [16], and factors like dyslipidaemia that 
impair endothelium-dependent vasomotion may play a role in the pathogenesis of primary hypertension 
[12,14]. Blood lipids, including LDL-C, have a number of non-atheromatous effects on blood vessels, 
which increase oxidative stress and inflammation, and promote elastin damage and deposition of 
calcium within the arterial wall [43,44]. LDL-C has been found to impair endothelial nitric oxide 
bioavailability through increased vascular production of reactive oxygen species and enhanced 
responses to vasoconstrictors like angiotensin II [15,17,45,46]. Therefore, the consequence of impaired 
endothelium-mediated dilatation in the resistance vessels would be the elevation of SVR. Twelve 
month treatment with statins improved flow-mediated dilatation in the brachial artery [25], while a 
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meta-analysis reported increased flow-mediated dilatation following treatment with pitavastatin [26]. 
As the deleterious effect of LDL-C on endothelial dysfunction can be reversed by statins, this provides 
a potential explanation for the beneficial effects of these agents on BP [20,24–26]. Experimental 
evidence suggests that LDL-C can increase the angiotensin II type 1 receptor density in the arterial wall 
[15,17], while statin treatment in vivo can reduce the vasoconstrictor responses elicited by angiotensin 
II in isolated human internal thoracic artery segments in vitro [47]. Collectively, the above findings 
support the view that LDL-C is a significant explanatory factor for BP via increased SVR. Supporting 
this view, plasma total cholesterol was recently found to be independently associated with the 
media:lumen ratio of small arteries obtained from humans by biopsy [48]. This variable that 
characterises resistance vessel structure is directly linked to the regulation of SVR [49]. 
The present results indicated that LDL-C was an independent determinant of AIx (models 1 and 2) and 
aortic pulse pressure (model 1), corresponding to previous findings [50,51]. AIx and central pulse 
pressure were higher in subjects with hypercholesterolemia than in controls [50]. Men with higher 
LDL-C level had increased AIx in all age groups, and a similar finding was observed in women under 
60 years of age [51]. A significant proportion of the reflected pressure wave originates from resistance 
arteries [49], and the level of augmentation is equally influenced by SVR and arterial stiffness [28]. 
Therefore, the association between LDL-C and wave reflection can be explained via SVR, the lowering 
of which reduces the magnitude of AIx. We also found an inverse relationship between smoking and 
SVR, which could be mediated via the vasodilating influence of carbon monoxide in tobacco smoke 
[52]. Unexpectedly, smoking showed a small inverse association with PWV, and we can speculate that 
lower SVR may also favour reductions in PWV. Of note, according to a comprehensive review, 
smoking has not influenced PWV in the majority of studies [9].  
The current study has limitations and the interpretation of the results must be done cautiously. 
Although the methods have been validated against invasive measurements, 3 dimensional ultrasound, 
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and tonometric recordings of PWV [28,32–34], the non-invasive evaluation of stroke volume and 
cardiac output is based on mathematical processing of the bioimpedance signal and simplification of 
physiology [33]. The supine recordings lasted 5 minutes, and this gives a rather narrow window of 
observation for the study of haemodynamics. However, when compared with single measurements of 
BP and heart rate, these continuous evaluations were still based on variables collected from more than 
300 cardiac cycles. The cross-sectional design does not allow conclusions about causal relationship, 
and the present findings should be confirmed in follow-up studies. As the haemodynamic recordings 
were performed in subjects who were themselves willing to participate, this makes a potential source 
for selections bias. Although the results were adjusted for multiple covariates that may be associated 
with LDL-C, the possibility of residual confounding remains. Finally, LDL-C and haemodynamics 
were measured during one single occasion, and repeated measurements of all variables would 
strengthen the findings. 
In conclusion, the present results showed that LDL-C was independently associated with BP and this 
effect could be attributed to elevated SVR that also resulted in enhanced wave reflection. Therefore, 
LDL-C could play a role in the pathogenesis of primary hypertension, possibly via its harmful 
influence on endothelium-dependent vasodilation. 
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FIGURE LEGENDS 
Figure 1. Supine aortic systolic (A) and diastolic (B) blood pressure, and aortic pulse pressure (C) and 
augmentation index (D) in age- and sex-adjusted quartiles (Q1-Q4) of LDL-cholesterol during 5-
minute recordings. Q1 (n=153), Q2 (n=158), Q3 (n=148) and Q4 (n=156); mean±standard error of the 
mean; *p<0.05, ANOVA for repeated measurements. 
Figure 2. Heart rate (A), cardiac index (B), systemic vascular resistance index (C), and pulse wave 
velocity (D) in age- and sex-adjusted quartiles of LDL- cholesterol during 5-minute recordings. 
Quartiles as in Figure 1; mean±standard error of the mean; *p<0.05, ANOVA for repeated 
measurements. 
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Figure 1. 
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Figure 2. 
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TABLE 1. Age and sex adjusted characteristics of the study population in quartiles of LDL cholesterol. 
 Overall Q1 Q2 Q3 Q4 
Number 615 153 158 148 156 
Male / female 314 / 301 80 / 73 79 / 79 75 / 73 80 / 76 
Age (years) 44.9 (11.9) 44.6 (11.8) 44.1 (12.6) 45.1 (12.6) 45.7 (10.7) 
Age range (years) 19-72 20-67 19-71 20-72 21-72 
BMI (kg/m2) 26.8 (4.4) 25.6 (4.5) 26.4 (4.5) 27.2 (4.1)* 28.1 (4.2)*† 
Alcohol (standard doses/week) 4.5 ( 5.7) 3.8 (4.9) 4.1 (5.1) 4.9 (6.5) 5.0 (6.3) 
Smokers (number / percentage) 70 / 11.4% 14 / 9.1% 16 / 10.1% 21 / 14.2% 25 / 16.0% 
Office blood pressure (mmHg)      
Systolic 140.5 (21.1) 134.7 (19.9) 138.8 (20.9) 139.4 (19.8)* 149.0 (20.9)*† 
Diastolic 89.3 (12.5) 85.3 (12.0) 88.6 (12.9) 90.0 (11.4)* 94.0(12.1)*† 
eGFR (ml/min per 1.73 m2) 98.8 (18.1) 102.0 (18.1)  101.3 (18.3)  97.7 (17.1) 94.2 (18.0)*† 
QUICKI 0.358 (0.042) 0.369 (0.041)  0.365 (0.056) 0.349 (0.032)*† 0.349 (0.032)*† 
Fasting plasma      
Creatinine (μmol/l) 73.7 ( 13.5) 72.2 (12.3) 74.8 (14.1) 74.1 (13.5) 73.6 (13.9) 
Cystatin C (mg/l) 0.85 (0.15) 0.82 (0.15) 0.83 (0.15) 0.85 (0.14) 0.89 (0.14)*† 
Sodium (mmol/l) 140.3 (2.0) 140.3 (2.1) 140.4 (2.0) 140.5 (2.0) 140.3 (1.7) 
Potassium (mmol/l) 3.81 (0.28) 3.82 (0.28) 3.81 (0.28) 3.84 (0.26) 3.77 (0.31) 
Uric acid (μmol/l) 303 (76) 291 (78) 297 (79) 310 (76) 312 (71) 
CRP (mg/l) 1.7 (2.9) 1.6 (3.0) 1.7 (4.1) 1.5 (1.5) 2.0 (2.2) 
Total cholesterol (mmol/l) 5.15 (1.02) 4.23 (0.68) 4.78 (0.64)* 5.33 (0.63)*† 6.25 (0.85)*† # 
Triglycerides (mmol/l) 1.23 (0.76) 1.05 (0.96) 1.17 (0.69) 1.23 (0.62) 1.49 (0.70)*† # 
HDL-C (mmol/l) 1.58 (0.44) 1.71 (0.488) 1.54 (0.41)* 1.56 (0.41)* 1.52 (0.43)* 
LDL-C cholesterol (mmol/l) 3.05 (0.95) 2.05 (0.51) 2.75 (0.48)* 3.26 (0.50)*† 4.15 (0.75)*†# 
Insulin (mU/L) 8.9 (17.0) 7.2 (5.6) 7.9 (6.1) 11.6 (33.3) 9.1 (5.4) 
Glucose (mmol/l) 5.44 (0.58) 5.34 (0.69) 5.40 (0.59) 5.49 (0.48) 5.55 (0.54)* 
Mean (standard deviation), *p<0.05 vs Q1; †p<0.05 vsQ2; #p<0.05 vs Q3; BMI, body mass index; eGFR, cystatin C based CDK-EPI formula for 
estimated glomerular filtration rate [31]; QUICKI, quantitative insulin sensitivity check index [30]; CRP, C-reactive protein; HDL-C, high density 
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol. 
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TABLE 2. Explanatory factors for haemodynamic variables in linear regression analyses with stepwise elimination. 
Aortic systolic blood pressure: model 1 Aortic systolic blood pressure: model 2 
 B Beta R squared p  B Beta R squared p 
(Constant) -16.615   0.738 (Constant) -98.362   0.044 
eGFR -0.222 -0.208 0.205 <0.001 PWV 77.269 0.377 0.306 <0.001 
LDL-C 3.343 0.165 0.259 <0.001 eGFR -0.187 -0.175 0.352 <0.001 
Age 0.332 0.204 0.285 <0.001 LDL-C 2.586 0.128 0.366 0.001 
BMI 0.531 0.122 0.304 0.003 Sodium 1.077 0.109 0.374 0.001 
Sodium 0.945 0.096 0.312 0.006 QUICKI -34.232 -0.076 0.380 0.036 
QUICKI -38.761 -0.086 0.317 0.026 HDL-C 4.509 0.103 0.384 0.005 
     BMI 0.434 0.099 0.389 0.014 
 
Aortic diastolic blood pressure: model 1 Aortic diastolic blood pressure: model 2 
 B Beta R squared p  B Beta R squared p 
(Constant) 19.283   0.588 (Constant) -32.811   0.316 
eGFR -0.204 -0.286 0.170 <0.001 PWV 54.974 0.401 0.244 <0.001 
LDL-C 2.265 0.168 0.217 <0.001 eGFR -0.155 -0.218 0.284 <0.001 
QUICKI -33.714 -0.112 0.238 0.005 QUICKI -35.114 -0.116 0.306 0.001 
Sex 2.564 0.099 0.252 0.008 Alcohol amount 0.198 0.088 0.317 0.011 
BMI 0.283 0.097 0.257 0.021 Sodium 0.628 0.095 0.324 0.005 
Sodium 0.525 0.080 0.261 0.032 Age -0.149 -0.137 0.330 0.006 
     LDL-C 1.466 0.109 0.337 0.006 
 
Aortic pulse pressure: model 1 Aortic pulse pressure: model 2 
 B Beta R squared p  B Beta R squared p 
(Constant) -46.757   0.092 (Constant) -50.479   0.076 
Age 0.307 0.354 0.206 <0.001 Age 0.190 0.219 0.206 <0.001 
BMI 0.355 0.152 0.223 <0.001 PWV 24.365 0.222 0.238 <0.001 
LDL-C 1.331 0.123 0.230 0.003 eGFR -0.047 -0.083 0.244 0.064 
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HDL-C 2.398 0.102 0.235 0.012 BMI 0.291 0.125 0.248 0.003 
Sodium 0.417 0.079 0.240 0.032 HDL-C 2.677 0.114 0.255 0.005 
     Sodium 0.393 0.074 0.259 0.041 
 
Augmentation index: model 1 Augmentation index: model 2 
 B Beta R squared p  B Beta R squared p 
(Constant) -1.268   0.414 (Constant) 7.678   0.016 
Age 0.576 0.570 0.350 <0.001 Age 0.532 0.527 0.350 <0.001 
Sex -9.060 -0.378 0.483 <0.001 Sex -9.687 -0.404 0.483 <0.001 
LDL-C 0.841 0.067 0.485 0.043 SVRI 0.005 0.247 0.549 <0.001 
     Heart rate -0.205 -0.164 0.576 <0.001 
     Smoker 2.930 0.080 0.583 0.003 
     BMI -0.240 -0.088 0.587 0.004 
     LDL-C 0.774 0.062 0.589 0.047 
 
Pulse wave velocity: model 1 Pulse wave velocity: model 2 
 B Beta R squared p  B Beta R squared p 
(Constant) 0.566   <0.001 (Constant) 0.916   <0.001 
Age 0.004 0.544 0.419 <0.001 Age 0.004 0.501 0.419 <0.001 
Uric acid 0.0002 0.172 0.493 <0.001 Aortic systolic 
blood pressure 
0.001 0.281 0.510 <0.001 
Triglycerides 0.013 0.102 0.509 0.002 Uric acid 0.0002 0.154 0.555 <0.001 
LDL-C 0.011 0.116 0.518 0.001 Triglycerides 0.012 0.095 0.568 0.003 
Smoker -0.023 -0.081 0.525 0.005 Smoker -0.019 -0.067 0.571 0.013 
BMI 0.002 0.080 0.528 0.019 HDL-C -0.019 -0.088 0.575 0.006 
     Sodium -0.003 -0.056 0.578 0.045 
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Systemic vascular resistance index: model 1 
 B Beta R squared p 
(Constant) 3417.956   <0.001 
eGFR -5.613 -0.172 0.106 <0.001 
Weight 9.149 0.246 0.142 <0.001 
Age 5.122 0.103 0.159 0.031 
Smoker -220.835 -0.123 0.171 0.001 
Height -8.445 -0.133 0.181 0.005 
LDL-C 64.294 0.104 0.188 0.016 
For all these analyses, the skewed distribution of pulse wave velocity (PWV) was Lg10 transformed. 
Variables in model 1: age, sex, body mass index (BMI) (for systemic vascular resistance BMI was replaced by height and weight), smoking status, 
consumption of standard drinks of alcohol per week, quantitative insulin sensitivity check index (QUICKI) [30], plasma C-reactive protein (CRP), 
sodium, uric acid, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, and cystatin C based 
CDK-EPI formula for estimated glomerular filtration rate (eGFR) [31].  
Variables in model 2: model 1 + PWV; for augmentation index: model 1 + heart rate, systemic vascular resistance index (SVRI), and PWV;  
for PWV: model 1 + aortic systolic blood pressure. 
 
